Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Cited by 19 Publications

Science, 2017, eaal3755

PubMed: 28302793

Sci Transl Med, 2018, 10(433)

PubMed: 29563317

Nat Chem Biol, 2016, 10.1038/nchembio.2082

PubMed: 27182663

ACS Appl Mater Interfaces, 2015, 10.1021/am5090226

PubMed: 25811662

Biomacromolecules, 2014, 15(11):4187-94

PubMed: 25251833

Int J Radiat Oncol, 2015, 91(4):807-16

PubMed: 25752395

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed:

Am J Cancer Res, 2017, 7(4):903-912

PubMed: 28469962

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313

Surgery, 2014, 10.1016/j.surg.2014.10.007

PubMed:

Am J Physiol Heart Circ Physiol, 2012, 71(13):4707-19

PubMed: 21555371
BMC Cancer, 2012, 12:541

PubMed: 23171055

RSC Adv, 2011, 1:884-892

PubMed:

Bioorg Med Chem, 2012, 21(4):922-31

PubMed: 23306053

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914

Biochem Biophys Res Commun, 2014, 453(3):392-7

PubMed: 25268318

J Nanopart Res, 2014, 16:2340

PubMed:

5 Customer Reviews

(F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.
Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.
Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Targets

Microtubule (human endothelial cells) ^[1]

0.1 pM

In vitro

Paclitaxel inhibits non-endothelial type human cells at 10⁴ - to 10⁵ -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. ^[1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. ^[2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
TE-15	Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMECwNlg4KM7:TR?=	MWfTRW5ITVJ?
LC-2-ad	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMECwN\|E4KM7:TR?=	MlPhV2FPT0WU
RL95-2	NUfLZYNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMECwOlY5KM7:TR?=	M2\aXXNCVkeHUh?=
MZ1-PC	M3vnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DIVWlEPTB;MD6wNFA4OjlizszN	NUTCU3Y4W0GQR1XS
TE-8	NVrIOHFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrrTWM2OD1yLkCwNVE4KM7:TR?=	NHrycXdUSU6JRWK=
SW954	NV[5UGM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7CbIxKSzVyPUCuNFAyOTlizszN	MVzTRW5ITVJ?
TE-11	Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\JUVh2UUN3ME2wMlAxOTJ\|IN88US=>	NFnvRlZUSU6JRWK=
PSN1	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3P2dGlEPTB;MD6wNFE{KM7:TR?=	MXrTRW5ITVJ?
MOLT-4	NXTafnBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHTUZRKSzVyPUCuNFAyPDlizszN	M4XxenNCVkeHUh?=
697	Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\FVoFKSzVyPUCuNFAyPSEQvF2=	NHvEdWRUSU6JRWK=
ETK-1	NUXW[4xrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlexTWM2OD1yLkCwNVUzKM7:TR?=	NX3I[2JQW0GQR1XS
TE-10	M4XJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwMECxOVQh\|ryP	M124XHNCVkeHUh?=
HUTU-80	M4HieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWD4ZW5tUUN3ME2wMlAxOTZ6IN88US=>	M2mzPXNCVkeHUh?=
NTERA-S-cl-D1	M3\VdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwMECyNFkh\|ryP	MmrrV2FPT0WU
MFH-ino	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnndZRRUUN3ME2wMlAxOjZ6IN88US=>	MofSV2FPT0WU
IA-LM	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPLSoRrUUN3ME2wMlAxOjhizszN	MXvTRW5ITVJ?
MC116	NXvnT21VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWO0R2tGUUN3ME2wMlAxOjh7IN88US=>	MkHhV2FPT0WU
RKO	MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\1TWM2OD1yLkCwNlk5KM7:TR?=	M4\uR3NCVkeHUh?=
MRK-nu-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2f0TGlEPTB;MD6wNFI6QSEQvF2=	M1LOTXNCVkeHUh?=
VA-ES-BJ	NGfDRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULRVZR3UUN3ME2wMlAxOyEQvF2=	NULaW3pHW0GQR1XS
KALS-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX:5S4J4UUN3ME2wMlAxOzB6IN88US=>	M1uzXnNCVkeHUh?=
BB30-HNC	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\id5JKSzVyPUCuNFA{OTRizszN	MYPTRW5ITVJ?
ACN	NXnkTnhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMECzNVYh\|ryP	M3LuXHNCVkeHUh?=
TE-9	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIq3[5FKSzVyPUCuNFA{OjZizszN	M1LQ[XNCVkeHUh?=
SIG-M5	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIe4UVhKSzVyPUCuNFA{OjdizszN	NGT2VINUSU6JRWK=
no-10	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\nTWM2OD1yLkCwN\|YzKM7:TR?=	MVHTRW5ITVJ?
EW-1	MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnY[5BKSzVyPUCuNFA{PzFizszN	NFHYR29USU6JRWK=
SK-LMS-1	Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHJbmpKSzVyPUCuNFA1ODFizszN	MlfrV2FPT0WU
GT3TKB	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfF[W9bUUN3ME2wMlAxPDN2IN88US=>	MWHTRW5ITVJ?
ES4	M37CVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4X2[2lEPTB;MD6wNFQ1QSEQvF2=	NHnJdnNUSU6JRWK=
IMR-5	NHzMd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPSV2pOUUN3ME2wMlAxPDVizszN	NXr5b2NKW0GQR1XS
NCI-H1648	NGPXR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwMEC0Olkh\|ryP	NXfS[5hUW0GQR1XS
MV-4-11	Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\CdnRKSzVyPUCuNFA1PzVizszN	NF;ZOpZUSU6JRWK=
SK-UT-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7kRY1LUUN3ME2wMlAxPDhizszN	NEHXOpBUSU6JRWK=
NB13	NWK4ZYQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPROZl3UUN3ME2wMlAxPDlzIN88US=>	M2X6NXNCVkeHUh?=
DJM-1	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXDNZZWUUN3ME2wMlAxPTNizszN	M2m5dHNCVkeHUh?=
ES8	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnNW2VWUUN3ME2wMlAxPTN6IN88US=>	NWGzfZZKW0GQR1XS
TE-6	NH3mW\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33uNGlEPTB;MD6wNFU4KM7:TR?=	M3zJfXNCVkeHUh?=
KS-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjLWFN4UUN3ME2wMlAxPTh{IN88US=>	NGnrWIlUSU6JRWK=
TE-1	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWeyNGxLUUN3ME2wMlAxPjB4IN88US=>	MmG3V2FPT0WU
ATN-1	MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMEC2NFkh\|ryP	MWfTRW5ITVJ?
A4-Fuk	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXiTWM2OD1yLkCwOlEyKM7:TR?=	MmX5V2FPT0WU
ALL-PO	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMEC2N{DPxE1?	M4XPfHNCVkeHUh?=
BE-13	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDWTWM2OD1yLkCwOlM3KM7:TR?=	NI\wVnpUSU6JRWK=
KM12	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwMEC2N\|ch\|ryP	NX3pVJF6W0GQR1XS
NOS-1	MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7VTWM2OD1yLkCwOlUh\|ryP	MoDnV2FPT0WU
SW962	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjHb4pKSzVyPUCuNFA3PjJizszN	NGTTOpJUSU6JRWK=
OCUB-M	M3mx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUf6fIpUUUN3ME2wMlAxPjZ{IN88US=>	MmXGV2FPT0WU
NCI-H510A	NY\XT3A4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7qTWM2OD1yLkCwOlY2KM7:TR?=	NIDEWJlUSU6JRWK=
EW-16	M2m3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2r1UGlEPTB;MD6wNFY6PCEQvF2=	M2rwWnNCVkeHUh?=
KGN	NFPpR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HYc2lEPTB;MD6wNFcyOiEQvF2=	MX3TRW5ITVJ?
LS-411N	M4q0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFOxSpVKSzVyPUCuNFA4OTdizszN	NF;FWWJUSU6JRWK=
Becker	M{LCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvsWXNKSzVyPUCuNFA4OiEQvF2=	M1;3dHNCVkeHUh?=
HC-1	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHFTWM2OD1yLkCwO\|IyKM7:TR?=	NIfxdINUSU6JRWK=
CESS	NUfXcZNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwMEC3N\|ch\|ryP	MVTTRW5ITVJ?
KURAMOCHI	NY[yNphWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrnTWM2OD1yLkCwO\|Q5KM7:TR?=	M{TESHNCVkeHUh?=
TGBC24TKB	MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMEC3OVIh\|ryP	MVfTRW5ITVJ?
SW982	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH65cZdKSzVyPUCuNFA4PjZizszN	MVPTRW5ITVJ?
HCE-4	M3TQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMEC3Olch\|ryP	M{jhWHNCVkeHUh?=
LOUCY	NXL2blYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7JTWM2OD1yLkCwO\|c2KM7:TR?=	MUXTRW5ITVJ?
8-MG-BA	MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlP6TWM2OD1yLkCwO\|k3KM7:TR?=	NFv0S3ZUSU6JRWK=
HT-144	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzER21KSzVyPUCuNFA5KM7:TR?=	Mn7zV2FPT0WU
LXF-289	NHrxN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPYO4NiUUN3ME2wMlAxQDF6IN88US=>	NUXodm44W0GQR1XS
RS4-11	NUXsdnJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fzNmlEPTB;MD6wNFg{PiEQvF2=	MkTEV2FPT0WU
DEL	NEHZNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjZZpJJUUN3ME2wMlAxQDR3IN88US=>	NVu2NGp7W0GQR1XS
OCI-AML2	M3LNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1OxbmlEPTB;MD6wNFg2OiEQvF2=	NFXzU2RUSU6JRWK=
CCRF-CEM	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULUTGdUUUN3ME2wMlAxQDdzIN88US=>	Mn7lV2FPT0WU
A388	NV7JSJdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmG5TWM2OD1yLkCwPFc1KM7:TR?=	Mny5V2FPT0WU
KNS-42	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLDb3RKSzVyPUCuNFA5QTFizszN	M4\PWXNCVkeHUh?=
OVCAR-4	NIX0c3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moi3TWM2OD1yLkCwPVA1KM7:TR?=	NIHVO2xUSU6JRWK=
NCI-H1355	MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jwNmlEPTB;MD6wNFkyPCEQvF2=	NV\LR29GW0GQR1XS
BL-70	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTBwMEC5N{DPxE1?	NHfUTXFUSU6JRWK=
BL-41	MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3ZTWM2OD1yLkCwPVM1KM7:TR?=	M17uOHNCVkeHUh?=
A101D	NH7pd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULUUnlsUUN3ME2wMlAxQTZizszN	M4LQe3NCVkeHUh?=
HL-60	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXy5dI5qUUN3ME2wMlAxQTZ4IN88US=>	NHTaU2FUSU6JRWK=
COR-L279	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwMEC5PVkh\|ryP	NX7tT3piW0GQR1XS
NCI-SNU-16	NHLhZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{L0ZWlEPTB;MD6wNVAxQCEQvF2=	NXvJOIZkW0GQR1XS
Calu-6	NYLiSXJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3H3RWlEPTB;MD6wNVAyOiEQvF2=	M4XFVHNCVkeHUh?=
SR	Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3KySmlEPTB;MD6wNVAzPiEQvF2=	NVjQS\|U4W0GQR1XS
QIMR-WIL	M3L1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjCfGdKSzVyPUCuNFExOzNizszN	M1PDR3NCVkeHUh?=
LB647-SCLC	MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULVUFR5UUN3ME2wMlAyODVzIN88US=>	M1\wSXNCVkeHUh?=
RPMI-8226	NFvUc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwMEGxNFIh\|ryP	MnS3V2FPT0WU
SK-PN-DW	M3HaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULQb2VMUUN3ME2wMlAyOTF{IN88US=>	NGjTTldUSU6JRWK=
SF268	M1Hm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMEGxOVEh\|ryP	NI\TfmhUSU6JRWK=
HD-MY-Z	NHi0PIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\OV2lEPTB;MD6wNVE3OyEQvF2=	MlznV2FPT0WU
DOHH-2	M3fYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[4O2lSUUN3ME2wMlAyOjB\|IN88US=>	MXHTRW5ITVJ?
SCC-3	MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LhNWlEPTB;MD6wNVIxPCEQvF2=	NHLWbIVUSU6JRWK=
ST486	MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPQTWM2OD1yLkCxNlA1KM7:TR?=	NXnpeXhZW0GQR1XS
NALM-6	M131VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwMEGyNVQh\|ryP	M4nnNnNCVkeHUh?=
NCI-H1436	NGewOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHoTWM2OD1yLkCxNlMyKM7:TR?=	NYHnV\|JsW0GQR1XS
KE-37	NHHtRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLuTWM2OD1yLkCxNlM1KM7:TR?=	NI\ybIRUSU6JRWK=
RPMI-8402	NEjEUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwMEGyOVYh\|ryP	NH;jdJRUSU6JRWK=
RXF393	MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHny[FVKSzVyPUCuNFEzPTdizszN	M3y5PHNCVkeHUh?=
KARPAS-45	NH[3OpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;DTWM2OD1yLkCxNlch\|ryP	NF3wRopUSU6JRWK=
HOP-62	NVH2cHNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjpTWM2OD1yLkCxNlc3KM7:TR?=	NInTOmxUSU6JRWK=
ES1	NVXOSVFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDqO5dKSzVyPUCuNFEzQDhizszN	NG\Zb4pUSU6JRWK=
L-363	M{PIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjFe3lKSzVyPUCuNFE{PTFizszN	M4XyfXNCVkeHUh?=
GI-1	NWfCSHdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXf5TZVyUUN3ME2wMlAyOzd\|IN88US=>	NXKx[lNIW0GQR1XS
CTV-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;VZ2lEPTB;MD6wNVQ4QCEQvF2=	NGm5WItUSU6JRWK=
TE-5	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMEG0PVYh\|ryP	NXTWPFh6W0GQR1XS
SNU-C2B	MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwMEG0PVYh\|ryP	MmXTV2FPT0WU
K-562	MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjhO5pUUUN3ME2wMlAyPTF4IN88US=>	MlXHV2FPT0WU
SNB75	M4iyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXlTWM2OD1yLkCxOVQh\|ryP	M1fKbHNCVkeHUh?=
MOLT-13	MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULPcmZ[UUN3ME2wMlAyPjN5IN88US=>	MUHTRW5ITVJ?
LS-123	NILafFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HjcGlEPTB;MD6wNVY3PCEQvF2=	NH:5c3JUSU6JRWK=
NCI-SNU-5	NXHXe2RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\kbG1KUUN3ME2wMlAyPzBzIN88US=>	MXTTRW5ITVJ?
Daudi	MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHwTWM2OD1yLkCxO\|A5KM7:TR?=	M3H4U3NCVkeHUh?=
A253	NVS2UmxOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rCOGlEPTB;MD6wNVc{QCEQvF2=	NEDzdJVUSU6JRWK=
TGBC1TKB	M2PVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMEG3OVIh\|ryP	MYnTRW5ITVJ?
SJSA-1	NVfpO4ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\hVFRKSzVyPUCuNFE4PjdizszN	NWTRfmlMW0GQR1XS
NCCIT	NHftWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwMEG3Olkh\|ryP	MYLTRW5ITVJ?
NCI-H69	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{G0V2lEPTB;MD6wNVc4QCEQvF2=	NYLmV5U1W0GQR1XS
SH-4	NHOwV\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDFTWM2OD1yLkCxPFk2KM7:TR?=	MUHTRW5ITVJ?
HCC1187	NWHJT3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMEG5NlQh\|ryP	NVvsfVVzW0GQR1XS
HCC1599	NXi3dZllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvYOnpKSzVyPUCuNFIxOiEQvF2=	MX\TRW5ITVJ?
ONS-76	NV7mPJNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3ywe2lEPTB;MD6wNlA{PiEQvF2=	NVz6b2ZuW0GQR1XS
KU812	M2nQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHiyTZVKSzVyPUCuNFIxOzlizszN	NHfMdJJUSU6JRWK=
ML-2	NGTlfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nlSmlEPTB;MD6wNlA1PyEQvF2=	MUHTRW5ITVJ?
HCE-T	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMEKwPVIh\|ryP	NWHKXm94W0GQR1XS
NCI-H446	NIjDd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrVSHZKSzVyPUCuNFIyOTJizszN	NIroU4VUSU6JRWK=
RPMI-6666	NFjTWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PxSWlEPTB;MD6wNlE1QSEQvF2=	NY\lTYQ{W0GQR1XS
MOLT-16	NGq1SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\TTWM2OD1yLkCyNVU{KM7:TR?=	NYDRWYFoW0GQR1XS
JiyoyeP-2003	NHfFXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7kUolKSzVyPUCuNFIyPzZizszN	NFOz[I9USU6JRWK=
MHH-PREB-1	M2G2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELoeHZKSzVyPUCuNFIyQTFizszN	MnXpV2FPT0WU
MC-CAR	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMEKzNlYh\|ryP	NIfLWFZUSU6JRWK=
BC-3	NYSydnJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMEKzOFQh\|ryP	MV\TRW5ITVJ?
KINGS-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3Hk[GlEPTB;MD6wNlM2PSEQvF2=	NHXIVllUSU6JRWK=
PF-382	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXRTXlKSzVyPUCuNFI{PzhizszN	MXfTRW5ITVJ?
J-RT3-T3-5	M3;5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XWPWlEPTB;MD6wNlM5OyEQvF2=	NETSNo1USU6JRWK=
SF539	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPrWIZKSzVyPUCuNFI1ODFizszN	NWnnbWxqW0GQR1XS
LB831-BLC	NUfzOYF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX36WVYxUUN3ME2wMlAzPDh3IN88US=>	NIG3S5RUSU6JRWK=
DMS-114	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\kPFFZUUN3ME2wMlAzPTB{IN88US=>	NYjkdZZSW0GQR1XS
LB1047-RCC	MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwMEK1NUDPxE1?	MXLTRW5ITVJ?
LB771-HNC	MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7XRmFKSzVyPUCuNFI2OzRizszN	M3q2NnNCVkeHUh?=
BB65-RCC	NGO0[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;yS2pOUUN3ME2wMlAzPTN2IN88US=>	NXPlRWJ2W0GQR1XS
BV-173	NHK2d3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;SS2lEPTB;MD6wNlU2PCEQvF2=	M4fVTnNCVkeHUh?=
ARH-77	M3i0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rVd2lEPTB;MD6wNlYxOSEQvF2=	MoDsV2FPT0WU
IST-MEL1	NVj4O4FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwMEK2NlMh\|ryP	MWDTRW5ITVJ?
NB1	NXHEcXVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M374fWlEPTB;MD6wNlY5PyEQvF2=	MVHTRW5ITVJ?
EoL-1-cell	NUe1R\|ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwMEK2PFgh\|ryP	NF21OFNUSU6JRWK=
KY821	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\od2lEPTB;MD6wNlY6PyEQvF2=	NVy5W41NW0GQR1XS
CMK	NF\1UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmOxTWM2OD1yLkCyO\|M1KM7:TR?=	NGjVbpNUSU6JRWK=
NCI-H2126	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFn3OnlKSzVyPUCuNFI4PjhizszN	NVSyNXRUW0GQR1XS
NCI-H526	NYL2cmE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjwPG97UUN3ME2wMlAzQDlzIN88US=>	MlfYV2FPT0WU
COLO-684	NIPqdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTOW2ZKSzVyPUCuNFI6ODhizszN	NX3JWJZ3W0GQR1XS
NCI-H747	NFvLWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnG1TWM2OD1yLkCyPVM{KM7:TR?=	M{T2THNCVkeHUh?=
JAR	M16zbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:5T\|ZMUUN3ME2wMlAzQTR4IN88US=>	NHPOTHpUSU6JRWK=
MEG-01	NV7EbXJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zBN2lEPTB;MD6wNlk4QCEQvF2=	NI\yfllUSU6JRWK=
MONO-MAC-6	NFLt[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXX0THB2UUN3ME2wMlA{ODJ\|IN88US=>	Ml:xV2FPT0WU
IST-SL1	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHnTWM2OD1yLkCzNFQzKM7:TR?=	NFnnbJNUSU6JRWK=
CPC-N	M4fEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHZWJBKSzVyPUCuNFMxPzlizszN	NI\3[2dUSU6JRWK=
NCI-H1963	NH7vcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXK[GJKSzVyPUCuNFMyOzFizszN	MoHBV2FPT0WU
K052	NXPocY1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4WzNmlEPTB;MD6wN\|I1PyEQvF2=	MmD0V2FPT0WU
KM-H2	NXTGb3E2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGi0dotKSzVyPUCuNFM{ODdizszN	MUXTRW5ITVJ?
TE-12	NVqxbJU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPvTWM2OD1yLkCzN\|A6KM7:TR?=	MmfrV2FPT0WU
TK10	M4XrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYraTYU{UUN3ME2wMlA{OzV4IN88US=>	M1:0[3NCVkeHUh?=
NMC-G1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMEO0OVIh\|ryP	MknTV2FPT0WU
no-11	MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NET4T3NKSzVyPUCuNFM1PzhizszN	M4\VXXNCVkeHUh?=
NCI-H524	NFLsW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMEO1Nlkh\|ryP	MkXSV2FPT0WU
MHH-CALL-2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\oTWM2OD1yLkCzOVYzKM7:TR?=	M2X6NnNCVkeHUh?=
GB-1	NIHnco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4[xZmlEPTB;MD6wN\|Yh\|ryP	NULLNXBCW0GQR1XS
OPM-2	Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnw[XFKSzVyPUCuNFM3PzNizszN	M{Tr[HNCVkeHUh?=
RH-1	NUnPc25GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMEO4NVkh\|ryP	NUW3eIRUW0GQR1XS
NCI-H64	NGHibnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1[xb2lEPTB;MD6wN\|g2PyEQvF2=	MmL2V2FPT0WU
EVSA-T	Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XXeGlEPTB;MD6wN\|kzOyEQvF2=	MkfVV2FPT0WU
KARPAS-299	NFuxTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7nU5ZKSzVyPUCuNFM6QCEQvF2=	MXXTRW5ITVJ?
MZ7-mel	M2r4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDLeI9uUUN3ME2wMlA1ODRizszN	NIGyR49USU6JRWK=
LB373-MEL-D	MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LwOmlEPTB;MD6wOFExPSEQvF2=	NVP2W2Y4W0GQR1XS
HEL	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlu1TWM2OD1yLkC0NVQh\|ryP	NUTUe4poW0GQR1XS
SW872	NYfG[Xl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mle3TWM2OD1yLkC0NlEh\|ryP	M3v3bXNCVkeHUh?=
DU-4475	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX[3V2k6UUN3ME2wMlA1OjR2IN88US=>	NGjMOldUSU6JRWK=
IST-SL2	M1W1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEn2R4JKSzVyPUCuNFQzPzVizszN	MmixV2FPT0WU
NCI-H82	NGntUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEP6XG5KSzVyPUCuNFQ{ODdizszN	NFjiRW5USU6JRWK=
LC4-1	NVzpVGtUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nlU2lEPTB;MD6wOFM2OSEQvF2=	MVPTRW5ITVJ?
HDLM-2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXwV2JKSzVyPUCuNFQ{QTJizszN	NXjRNJl4W0GQR1XS
MMAC-SF	NYfpUnBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnjS3hKUUN3ME2wMlA1PTN2IN88US=>	MmnQV2FPT0WU
L-540	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfCWnNKSzVyPUCuNFQ3OzlizszN	MoryV2FPT0WU
MZ2-MEL	NUWwfHVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljwTWM2OD1yLkC0O\|QzKM7:TR?=	MXHTRW5ITVJ?
LU-134-A	NGHLcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnPTWM2OD1yLkC0O\|c{KM7:TR?=	MXrTRW5ITVJ?
UACC-257	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwMES4OFkh\|ryP	NVLqUll1W0GQR1XS
NCI-H1581	NH72bG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Gz[mlEPTB;MD6wOFk2OyEQvF2=	MUfTRW5ITVJ?
NB17	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTBSHRmUUN3ME2wMlA1QTd7IN88US=>	MWXTRW5ITVJ?
SBC-1	M4DJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTtVY5GUUN3ME2wMlA2ODR{IN88US=>	M1fYV3NCVkeHUh?=
TALL-1	NV;JSVR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUL3XoxuUUN3ME2wMlA2ODR3IN88US=>	NFnxOmRUSU6JRWK=
NCI-H1304	M3rlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHKxS4lKSzVyPUCuNFUzODhizszN	MnjGV2FPT0WU
NEC8	MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF2zSZVKSzVyPUCuNFUzQDZizszN	NEO0dXVUSU6JRWK=
CAL-148	MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwMEW0N\|kh\|ryP	MWnTRW5ITVJ?
CGTH-W-1	Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPkTFhKSzVyPUCuNFU1PDlizszN	Mo\mV2FPT0WU
NCI-H889	Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrMbZRKSzVyPUCuNFU2QTJizszN	NGTBbZBUSU6JRWK=
GR-ST	M2S3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnUPXhKSzVyPUCuNFU3OjFizszN	MVfTRW5ITVJ?
KARPAS-422	NGH6XWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMEW2OUDPxE1?	Ml7qV2FPT0WU
RPMI-8866	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PlcWlEPTB;MD6wOVcyOiEQvF2=	NXq2dIZMW0GQR1XS
SCLC-21H	NE\uVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NES2VnBKSzVyPUCuNFU5QDRizszN	M2PMZ3NCVkeHUh?=
COR-L88	M3KxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjs[ZpSUUN3ME2wMlA2QTJ5IN88US=>	MUDTRW5ITVJ?
LU-139	NX\FdmJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwMEW5PFYh\|ryP	NGDvcnJUSU6JRWK=
SF126	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4f6VGlEPTB;MD6wOlE{OyEQvF2=	MUTTRW5ITVJ?
NCI-H1882	MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorzTWM2OD1yLkC2OFI1KM7:TR?=	NHzTUZVUSU6JRWK=
EW-24	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[1WGlEPTB;MD6wOlQ5OyEQvF2=	MVvTRW5ITVJ?
CP67-MEL	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLlTWM2OD1yLkC2PFEh\|ryP	NH33S5RUSU6JRWK=
DG-75	NHH6bHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\ycFZJUUN3ME2wMlA3QDl7IN88US=>	NGHmdGVUSU6JRWK=
LOXIMVI	M4rPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nIS2lEPTB;MD6wO\|AzQCEQvF2=	NGr3PHBUSU6JRWK=
HH	NGe0fW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIC1e\|NKSzVyPUCuNFcyPTdizszN	MkHqV2FPT0WU
K5	MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7qO\|FKSzVyPUCuNFczOjZizszN	M{LJbnNCVkeHUh?=
EC-GI-10	M3jW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwMEeyOVch\|ryP	M{LtWnNCVkeHUh?=
SK-N-DZ	MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HEVWlEPTB;MD6wO\|MxPyEQvF2=	MYrTRW5ITVJ?
A3-KAW	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHQT5FKSzVyPUCuNFc{PTFizszN	M4XQUnNCVkeHUh?=
MLMA	M4XGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwMEe0OlUh\|ryP	MoW4V2FPT0WU
LB996-RCC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPYcXRKSzVyPUCuNFc4ODdizszN	NUTLUZR[W0GQR1XS
OS-RC-2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4e5W2lEPTB;MD6wO\|c1QCEQvF2=	MX3TRW5ITVJ?
CTB-1	M{XMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jUTWlEPTB;MD6wO\|gyKM7:TR?=	MXfTRW5ITVJ?
IST-MES1	MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1:yZWlEPTB;MD6wO\|kyOiEQvF2=	NYXkbZg4W0GQR1XS
LS-1034	NFW4cYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXHZpIzUUN3ME2wMlA5ODN3IN88US=>	MUPTRW5ITVJ?
HT	NYrwTpBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPnZXNLUUN3ME2wMlA5ODh4IN88US=>	NV3kdItnW0GQR1XS
NCI-H2141	NYXZVYgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMEixJO69VQ>?	MoruV2FPT0WU
LB2518-MEL	M1nWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXVO2o2UUN3ME2wMlA5OTRzIN88US=>	MorCV2FPT0WU
GI-ME-N	Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnnTWM2OD1yLkC4OFUzKM7:TR?=	NVzwdmlEW0GQR1XS
TGW	NGTRRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2n4NWlEPTB;MD6wPFYxPyEQvF2=	M3jXN3NCVkeHUh?=
SK-NEP-1	NEXXVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnqTWM2OD1yLkC4OlQyKM7:TR?=	NIK3T5VUSU6JRWK=
NOMO-1	NUG5WFlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDxXYpKSzVyPUCuNFkzPzVizszN	Mn7OV2FPT0WU
ES6	NX7u[Wp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHuZoxKSzVyPUCuNFk2QDlizszN	NHyxO3pUSU6JRWK=
NCI-H209	Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LOfmlEPTB;MD6wPVc5PiEQvF2=	NHrzVpRUSU6JRWK=
GAK	MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HRWWlEPTB;MD6xNFE3KM7:TR?=	MYHTRW5ITVJ?
BC-1	NYnyPFJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMUCzOlEh\|ryP	NWGwTo1yW0GQR1XS
KLE	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\oSFFPUUN3ME2wMlExPDR\|IN88US=>	MWjTRW5ITVJ?
EW-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPXTWM2OD1yLkGwPVgh\|ryP	MXjTRW5ITVJ?
NKM-1	MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMUGxJO69VQ>?	MUTTRW5ITVJ?
D-336MG	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLYNVBKSzVyPUCuNVEzPDRizszN	MoDYV2FPT0WU
NB69	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\KemhCUUN3ME2wMlEyOzBzIN88US=>	MmTnV2FPT0WU
D-263MG	NHjvRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIP4WGVKSzVyPUCuNVE4OTJizszN	Moj1V2FPT0WU
KP-N-YS	NWLJZYtwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHYTWM2OD1yLkGyNlkyKM7:TR?=	NYOzWZNEW0GQR1XS
NCI-H1155	MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMUK1OVgh\|ryP	MWLTRW5ITVJ?
BOKU	M3HpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMUK1O\|kh\|ryP	MYXTRW5ITVJ?
LAMA-84	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2T1[2lEPTB;MD6xNlk6KM7:TR?=	NGfsOoJUSU6JRWK=
Raji	M3PvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHuepZKSzVyPUCuNVMyOTdizszN	NIn0O3RUSU6JRWK=
LU-65	NFnOXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMUOzNFch\|ryP	MVHTRW5ITVJ?
NCI-H187	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXtT5RrUUN3ME2wMlE{QTJ2IN88US=>	NETF[VhUSU6JRWK=
GCIY	NVr2W3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF60c5ZKSzVyPUCuNVQ6ODFizszN	MmD6V2FPT0WU
NCI-H2107	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwMUWwPEDPxE1?	MWnTRW5ITVJ?
NCI-H1522	NX\S[W1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXuxOopRUUN3ME2wMlE2OjZ4IN88US=>	NGPFfIJUSU6JRWK=
NB6	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMUW2NlMh\|ryP	NHrHWZZUSU6JRWK=
EM-2	NFyxfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvLTWM2OD1yLkG1O\|A3KM7:TR?=	NWLKPYM6W0GQR1XS
HCC2218	M1WxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjITWM2OD1yLkG1PVgh\|ryP	MoLJV2FPT0WU
NCI-H748	NGfuephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\MdXR7UUN3ME2wMlE3Ozd4IN88US=>	NIjLSlZUSU6JRWK=
MS-1	NHfGVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMU[1N\|ch\|ryP	MkfPV2FPT0WU
NB5	MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDKVHhKSzVyPUCuNVY2QTdizszN	NVy5ZWRYW0GQR1XS
OMC-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPJO2twUUN3ME2wMlE3Pjh6IN88US=>	NX3SZoJqW0GQR1XS
NCI-H345	NVPzc4NzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMU[5Nlgh\|ryP	MojPV2FPT0WU
L-428	NWft[o1CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwMU[5OFUh\|ryP	NGjjWmNUSU6JRWK=
SCH	NVH1coQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\hW5BiUUN3ME2wMlE5Pjh3IN88US=>	NHLsV5NUSU6JRWK=
NCI-H1417	Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMUmyNlch\|ryP	Mn7RV2FPT0WU
COLO-320-HSR	M4fhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;LV2lEPTB;MD6xPVU{OiEQvF2=	MlHXV2FPT0WU
BT-474	M3O1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLlSFdKSzVyPUCuNlA5QTJizszN	NUDpemZ2W0GQR1XS
GDM-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPQTWM2OD1yLkKxPVcyKM7:TR?=	MY\TRW5ITVJ?
NCI-H2196	MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfmb3dNUUN3ME2wMlIzOjN3IN88US=>	NY\3fWM5W0GQR1XS
KP-N-RT-BM-1	M2TjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUe3[3pOUUN3ME2wMlIzOzR7IN88US=>	NV\zRYE1W0GQR1XS
KNS-81-FD	MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfDOXVGUUN3ME2wMlIzQTV6IN88US=>	MWDTRW5ITVJ?
COLO-668	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMkO2O\|Uh\|ryP	MlP0V2FPT0WU
C2BBe1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1:wdmlEPTB;MD6yOlc1PyEQvF2=	NHi0SWxUSU6JRWK=
Ramos-2G6-4C10	NVH5b3FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwMk[5OVQh\|ryP	MU\TRW5ITVJ?
CAS-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7KTJNKSzVyPUCuNlcxQTZizszN	MXPTRW5ITVJ?
GOTO	MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX:xdINNUUN3ME2wMlI4QDl2IN88US=>	MU\TRW5ITVJ?
LP-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMkiwOVch\|ryP	MWXTRW5ITVJ?
NCI-SNU-1	NGrzU\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;DemlEPTB;MD6yPVQzOiEQvF2=	NVn1fotzW0GQR1XS
EB-3	NEXkUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXaXmdqUUN3ME2wMlI6QTd7IN88US=>	Ml\RV2FPT0WU
MHH-NB-11	M4HCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXpTWM2OD1yLkOwOFAzKM7:TR?=	M1rYb3NCVkeHUh?=
SK-N-FI	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fxT2lEPTB;MD6zNVY6OiEQvF2=	MUPTRW5ITVJ?
HCC2157	Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrsPZBKSzVyPUCuN\|M6OTNizszN	MoHtV2FPT0WU
SIMA	NFr3ZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLsTWM2OD1yLkO0OVgyKM7:TR?=	MkjpV2FPT0WU
MDA-MB-134-VI	NHzNboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHEV4pOUUN3ME2wMlM3QTJ6IN88US=>	MonvV2FPT0WU
NCI-H1694	NEC3U3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDlelJKSzVyPUCuN\|ch\|ryP	MUXTRW5ITVJ?
EHEB	NYjQd\|lxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoSxTWM2OD1yLkO5NFg2KM7:TR?=	NHrYU45USU6JRWK=
U-266	NXvXZXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HR[WlEPTB;MD6zPVg1PiEQvF2=	NUf0WmdzW0GQR1XS
LC-1F	NV;mZ4w6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDXNZNKSzVyPUCuOFM4PjVizszN	MYjTRW5ITVJ?
SHP-77	M{PFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvuUFdKSzVyPUCuOFc5PTVizszN	NEL2TlRUSU6JRWK=
LS-513	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHIVlVxUUN3ME2wMlQ6OzB5IN88US=>	NEi2NY1USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. ^[4]

Protocol

Cell Research: ^[1]	+ Expand Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs Concentrations: 0.1-100 pM Incubation Time: 72 hours Method: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well. (Only for Reference)
Animal Research: ^[5]	+ Expand Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use. Dosages: 20 mg/kg Administration: Administered via i.v. (Only for Reference)

Cell Research:

^[1]

+ Expand

Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
Concentrations: 0.1-100 pM
Incubation Time: 72 hours
Method:
Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

(Only for Reference)

Animal Research:

^[5]

+ Expand

Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
Dosages: 20 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

[4] Chang J, et al. Breast Cancer Res Treat. 2012.

+ Expand

Solubility (25°C)

In vitro	DMSO	171 mg/mL (200.25 mM)
	Ethanol	18 mg/mL (21.07 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+5% Tween 80+ddH2O For best results, use promptly after mixing.	2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Paclitaxel SDF

Molecular Weight	853.91
Formula	C₄₇H₅₁NO₁₄
CAS No.	33069-62-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC 125973

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03694002	Recruiting	Locally Advanced Thymic Carcinoma\|Metastatic Thymic Carcinoma\|Recurrent Thymic Carcinoma\|Unresectable Thymic Carcinoma	Southwest Oncology Group\|National Cancer Institute (NCI)	August 9 2018	Phase 2
NCT03275818	Recruiting	Tumor Desmoplastic Small Round Cell Adult\|Tumor Desmoplastic Small Round Cell Childhood\|Sarcoma Ewing\|Sarcoma\|Desmoid	Grupo Espanol de Investigacion en Sarcomas	May 9 2017	Phase 2
NCT03057600	Active not recruiting	Triple Negative Breast Cancer\|TNBC - Triple-Negative Breast Cancer	Calithera Biosciences Inc	May 9 2017	Phase 2
NCT02775435	Active not recruiting	Non-small Cell Lung Cancer	Merck Sharp & Dohme Corp.	June 9 2016	Phase 3
NCT02181634	Completed	Cholangiocarcinoma	PrECOG LLC.\|Celgene Corporation	December 9 2014	Phase 2
NCT02415023	Completed	Gastric Cancer	Hutchison Medipharma Limited	November 9 2014	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?
Answer:
S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.
Question 2:
the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?
Answer:
Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Vincristine sulfate

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (EPO906, Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 19 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 19 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)